Intellipharmaceutics International Stock Cash And Equivalents
| IPCIFDelisted Stock | USD 0.04 0.00 0.00% |
Intellipharmaceutics International fundamentals help investors to digest information that contributes to Intellipharmaceutics' financial success or failures. It also enables traders to predict the movement of Intellipharmaceutics OTC Stock. The fundamental analysis module provides a way to measure Intellipharmaceutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Intellipharmaceutics otc stock.
Intellipharmaceutics |
Intellipharmaceutics International OTC Stock Cash And Equivalents Analysis
Intellipharmaceutics' Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.
Current Intellipharmaceutics Cash And Equivalents | 79.65 K |
Most of Intellipharmaceutics' fundamental indicators, such as Cash And Equivalents, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Intellipharmaceutics International is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually three months).
CompetitionIn accordance with the recently published financial statements, Intellipharmaceutics International has 79.65 K in Cash And Equivalents. This is 99.99% lower than that of the Pharmaceuticals sector and 99.98% lower than that of the Health Care industry. The cash and equivalents for all United States stocks is 100.0% higher than that of the company.
Intellipharmaceutics Cash And Equivalents Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Intellipharmaceutics' direct or indirect competition against its Cash And Equivalents to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of Intellipharmaceutics could also be used in its relative valuation, which is a method of valuing Intellipharmaceutics by comparing valuation metrics of similar companies.Intellipharmaceutics is currently under evaluation in cash and equivalents category among its peers.
Intellipharmaceutics Fundamentals
| Return On Asset | -0.98 | ||||
| Operating Margin | (106.06) % | ||||
| Current Valuation | 4.47 M | ||||
| Shares Outstanding | 33.09 M | ||||
| Shares Owned By Insiders | 1.70 % | ||||
| Shares Owned By Institutions | 11.09 % | ||||
| Number Of Shares Shorted | 714 K | ||||
| Price To Earning | (0.50) X | ||||
| Price To Sales | 66.19 X | ||||
| Gross Profit | 1.4 M | ||||
| EBITDA | (4.45 M) | ||||
| Net Income | (5.15 M) | ||||
| Cash And Equivalents | 79.65 K | ||||
| Total Debt | 2.01 M | ||||
| Debt To Equity | 165.20 % | ||||
| Current Ratio | 0.05 X | ||||
| Book Value Per Share | (0.31) X | ||||
| Cash Flow From Operations | (2.46 M) | ||||
| Short Ratio | 0.39 X | ||||
| Earnings Per Share | (0.16) X | ||||
| Target Price | 25.0 | ||||
| Number Of Employees | 11 | ||||
| Beta | 1.0 | ||||
| Market Capitalization | 2.02 M | ||||
| Total Asset | 2.1 M | ||||
| Retained Earnings | (86.55 M) | ||||
| Working Capital | (5.62 M) | ||||
| Current Asset | 1.41 M | ||||
| Current Liabilities | 7.02 M | ||||
| Z Score | -65.8 | ||||
| Net Asset | 2.1 M |
About Intellipharmaceutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Intellipharmaceutics International's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Intellipharmaceutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Intellipharmaceutics International based on its fundamental data. In general, a quantitative approach, as applied to this otc stock, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| BTC | Bitcoin | |
| TRX | TRON | |
| BNB | Binance Coin | |
| ADA | Cardano | |
| XRP | XRP |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Commodity Channel module to use Commodity Channel Index to analyze current equity momentum.
Other Consideration for investing in Intellipharmaceutics OTC Stock
If you are still planning to invest in Intellipharmaceutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Intellipharmaceutics' history and understand the potential risks before investing.
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities |